Skip to main content

Peer Review reports

From: Activity and safety of SHR3680, a novel antiandrogen, in patients with metastatic castration-resistant prostate cancer: a phase I/II trial

Original Submission
15 Nov 2021 Submitted Original manuscript
8 Dec 2021 Reviewed Reviewer Report
8 Dec 2021 Reviewed Reviewer Report
5 Jan 2022 Author responded Author comments - Xiaojian Qin
Resubmission - Version 2
5 Jan 2022 Submitted Manuscript version 2
17 Jan 2022 Reviewed Reviewer Report
18 Jan 2022 Author responded Author comments - Xiaojian Qin
Resubmission - Version 3
18 Jan 2022 Submitted Manuscript version 3
Publishing
18 Jan 2022 Editorially accepted
4 Mar 2022 Article published 10.1186/s12916-022-02263-x

You can find further information about peer review here.

Back to article page